Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD138-IFNα2 fusion protein
- Development stage
- Preclinical
- Lead developer
- Nammi Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
anti-CD138-IFNα2 fusion protein is a masked immunocytokine being developed by Qwixel Therapeutics for the treatment of CD138-positive malignancies, including multiple myeloma and ovarian cancer. The molecule consists of an anti-CD138 (Syndecan-1) monoclonal antibody fused to interferon alpha-2 (IFNα2), featuring a tumor-selectively cleaved peptide mask. This masking technology is designed to prevent the IFNα2 payload from binding to its receptors (IFNAR) in systemic circulation, thereby minimizing the dose-limiting toxicities typically associated with recombinant interferon therapies. Upon reaching the tumor microenvironment, the mask is cleaved by tumor-associated proteases, releasing active IFNα2 to exert direct anti-proliferative effects on tumor cells and stimulate a localized immune response.
- Other names
- anti-CD138-IFNα2CD138-IFNα2 fusion proteinmasked anti-CD138-IFNα2 fusion protein
02
Targets
SDC1 (Syndecan-1)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on anti-CD138-IFNα2 fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD138-IFNα2 fusion protein.